Adding to the debate about the potential need for repeat Lp(a) testing comes an analysis of Lp(a) measurements from participants in the placebo arm of the ODYSSEY OUTCOMES study of PCSK9i therapy with alirocumab in high risk patients on optimised statin therapy following an acute coronary syndrome (ACS) event.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
